で公開中です! 詳しく見る
KTTAWのアイコン

Pasithea Therapeutics Warrants
KTTAW

上場廃止済み

KTTAWは2026年9月15日に上場廃止となりました。

 

概要: Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

従業員数: 5

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 0%
ネガティブ 0%

KTTAWに関する最近のニュース記事はまだ届いていません。

価格チャートは Lightweight Charts™ を使用して実装されています